Viking Global Investors
REGN icon

Viking Global Investors’s Regeneron Pharmaceuticals REGN Stock Holding History

Viking Global Investors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-97,739
Closed -$62M – 103
2025
Q1 		$62M Buy
+97,739
New +$67.2M 0.2% 73
2024
Q4 		– Sell
-49,870
Closed -$52.4M – 99
2024
Q3 		$52.4M Buy
+49,870
New +$55.5M 0.19% 71
2014
Q4 		– Sell
-1,080,682
Closed -$390M – 79
2014
Q3 		$390M Sell
1,080,682
-1,882,774
-64% -$631M 1.56% 27
2014
Q2 		$837M Buy
2,963,456
+1,911,656
+182% +$567M 3.65% 10
2014
Q1 		$316M Buy
+1,051,800
New +$324M 1.32% 25

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Viking Global Investors's REGN Position: Q2 2025 in Review

Viking Global Investors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 97,739 shares — an estimated $62M sold.

Viking Global Investors first reported a position in REGN in Q1 2014 and held it in 5 quarters. The position peaked at $837M in Q2 2014. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Viking Global Investors reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Viking Global Investors sold 97,739 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $62M.
  • Viking Global Investors first reported a position in Regeneron Pharmaceuticals in Q1 2014 and held it in 5 quarters.
  • Viking Global Investors's Regeneron Pharmaceuticals position peaked at $837M in Q2 2014.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Viking Global Investors's 13F filing for Q2 2025, filed 14 Aug 2025.